Chemosensitizing and Nephroprotective Effect of Resveratrol in Cisplatin -treated Animals

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2015 Feb 25

PMID 25709558

Citations 14

Authors

Abdel-Moneim M Osman

Suad A Telity

Saud A Telity

Zoheir A Damanhouri

Sameer E Al-Harthy

Huda M Al-Kreathy

Wafaa S Ramadan

Mohamed F Elshal

Lateef M Khan

Fatemah Kamel

Affiliations

Soon will be listed here.

Abstract

Background: Cisplatin (CIS) is one of the most effective anticancer drug used in the treatment of several solid tumors .Its use is limited by its nephrotoxicity. The present study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of CIS and the possible protective effect against CIS-induced nephrotoxicity in rats.

Methods: The percent survival of female tumor bearing mice was used for determination the cytotoxic activity of CIS in the presence or the absence of RSVL. Uptake and cell cycle effect, serum creatinine (CREA), blood urea nitrogen (BUN), Reduced Glutathione (GSH) and histopatholgical examination of kidney tissues after CIS and/or RSVL therapy were also investigated.

Results: RSVL increased the intracellular level of CIS in EAC cells and there was a strong correlation between the high cellular level of CIS and its cytotoxicity. CIS at a dose level of 5 mg/kg increased the mean survival time of female tumor bearing mice to 25 days compared with 17 days for tumor-bearing control mice. Administration of RSVL at a dose level of 25 mg/kg simultaneously with CIS increased the mean survival time to 48 days with 60% survival of the tumor-bearing animals. Cell cycle analysis of tumor cells showed that CIS treatment decreases the proliferation index of tumor cells while in presence of RSVL there was more significant inhibitions. Also, CIS treatment caused increase in level of creatinine and blood urea with significant decrease in the GSH level. While, in the presence of RSVL, level of creatinine and blood urea restored to control level.

Conclusion: This study suggests that RSVL could increase the cytotoxic activity of CIS and protect against its nephrotoxicity.

Citing Articles

Implication of MAPK, Lipocalin-2, and Fas in the protective action of liposomal resveratrol against isoproterenol-induced kidney injury.

Alhusaini A, Alshehri S, Sarawi W, Alghibiwi H, Alturaif S, Al Khbiah R Saudi Pharm J. 2024; 32(1):101907.

PMID: 38178854 PMC: 10764257. DOI: 10.1016/j.jsps.2023.101907.

Cisplatin-Induced Kidney Toxicity: Potential Roles of Major NAD-Dependent Enzymes and Plant-Derived Natural Products.

Iskander A, Yan L Biomolecules. 2022; 12(8).

PMID: 36008971 PMC: 9405866. DOI: 10.3390/biom12081078.

Esculetin has therapeutic potential via the proapoptotic signaling pathway in A253 human submandibular salivary gland tumor cells.

Park S, Jung W, Kim H, Yu H, Kim Y, Kim J Exp Ther Med. 2022; 24(2):533.

PMID: 35837055 PMC: 9257944. DOI: 10.3892/etm.2022.11460.

Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting Ferroptosis.

Zhou L, Yu P, Wang T, Du Y, Chen Y, Li Z Oxid Med Cell Longev. 2022; 2022:9947191.

PMID: 35075382 PMC: 8783728. DOI: 10.1155/2022/9947191.

Regulation of Cytochrome Oxidase by Natural Compounds Resveratrol, (-)-Epicatechin, and Betaine.

Lee I Cells. 2021; 10(6).

PMID: 34072396 PMC: 8229178. DOI: 10.3390/cells10061346.

References

Beutler E, Duron O, Kelly B . Improved method for the determination of blood glutathione. J Lab Clin Med. 1963; 61:882-8. View

Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1999; 34(10):1522-34. DOI: 10.1016/s0959-8049(98)00224-x. View

Herzog C, Tsokos M, Bates S, Fojo A . Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem. 1993; 268(4):2946-52. View

Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E . Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle. 2012; 11(18):3472-80. PMC: 3466557. DOI: 10.4161/cc.21789. View

Rezk Y, Balulad S, Keller R, Bennett J . Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol. 2006; 194(5):e23-6. DOI: 10.1016/j.ajog.2005.11.030. View

Matsushima H, Yonemura K, Ohishi K, Hishida A . The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med. 1998; 131(6):518-26. DOI: 10.1016/s0022-2143(98)90060-9. View

Gupta S, Kannappan R, Reuter S, Kim J, Aggarwal B . Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011; 1215:150-60. PMC: 3060406. DOI: 10.1111/j.1749-6632.2010.05852.x. View

Galea A, Murray V . The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta. 2002; 1579(2-3):142-52. DOI: 10.1016/s0167-4781(02)00535-3. View

Behling E, Sendao M, Francescato H, Antunes L, Costa R, Bianchi M . Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol Rep. 2006; 58(4):526-32. View

10.

Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R . A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994; 269(30):19488-93. View

11.

Osman A, Bayoumi H, Al-Harthi S, Damanhouri Z, Elshal M . Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int. 2012; 12(1):47. PMC: 3537590. DOI: 10.1186/1475-2867-12-47. View

12.

Zhou B, Elledge S . The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408(6811):433-9. DOI: 10.1038/35044005. View

13.

Vitrac X, Bornet A, Vanderlinde R, Valls J, Richard T, Delaunay J . Determination of stilbenes (delta-viniferin, trans-astringin, trans-piceid, cis- and trans-resveratrol, epsilon-viniferin) in Brazilian wines. J Agric Food Chem. 2005; 53(14):5664-9. DOI: 10.1021/jf050122g. View

14.

Wolfgang G, Dominick M, Walsh K, Hoeschele J, Pegg D . Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol. 1994; 22(1):73-9. DOI: 10.1006/faat.1994.1010. View

15.

Levi J, Jacobs C, Kalman S, McTigue M, Weiner M . Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther. 1980; 213(3):545-50. View

16.

Walworth N . Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol. 2000; 12(6):697-704. DOI: 10.1016/s0955-0674(00)00154-x. View

17.

Nessa M, Beale P, Chan C, Yu J, Huq F . Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res. 2012; 32(1):53-9. View

18.

Zhang J, Lindup W . Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol. 1993; 45(11):2215-22. View

19.

Osman A, Al-Harthi S, Alarabi O, Elshal M, Ramadan W, Alaama M . Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int. 2013; 13:52. PMC: 3680308. DOI: 10.1186/1475-2867-13-52. View

20.

Khynriam D, Prasad S . Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol Toxicol. 2002; 18(6):349-58. DOI: 10.1023/a:1020899221192. View